📱 #ASCOAI: Personalized digital education may strengthen hereditary #Cancer counseling. The AYA-RISE chatbot improved risk comprehension in young patients using guideline-based content and predefined conversations, not generative #AI. Learn more ➡️ ascoai.org/articles/2026/10/…

🫁 Claudia Henschke, PhD, MD, helped transform #LungCancer screening through pioneering research on early detection with low-dose CT. @RajaFlores reflects on her extraordinary career, scientific legacy, and personal impact. Read the full dedication 👉 ascopost.com/news/october-20…

🚨 #FDAApproval: The @FDA has granted traditional approval to pembrolizumab (Keytruda) and Keytruda Qlex for previously treated, unresectable or metastatic TMB-H solid tumors (≥13 mut/Mb) with no satisfactory alternatives. 🔗 ascopost.com/news/october-20…

🩻 The phase 3️⃣ RT CHARM trial found that a 3-week course of postmastectomy radiation therapy was safe and noninferior to a 5-week course for reconstruction complications in women with #BreastCancer. 🔹Matthew Poppe, MD of @huntsmancancer | @JCO_ASCO 🔗 ascopost.com/news/october-20…

🫁 At today's 50th I-ELCAP Conference, @AltorkiNasser discussed how early #lungcancer detection is transforming surgical management. By identifying cancers sooner, patients may have more opportunities for surgical resection and potentially curative treatment. #IELCAP

🩸The treatment landscape for relapsed/refractory #DLBCL continues to evolve. At the @NCCN Hem Congress, Jeremy S. Abramson, MD, MMSc, discusses how #CARTcell therapy, bispecific antibodies, and novel combinations are reshaping treatment sequencing. 🔗 ️ ascopost.com/news/october-20…

🥼#ASCOAI: A scoping review identified 5 studies of intraoperative #AI decision support, revealing significant gaps in clinical validation, ethical governance and regulatory reporting. ☑️ Findings highlight challenges in translating AI into surgical care ascoai.org/articles/2026/10/…

📸 Facial image analysis may offer a new approach to #cancerrisk assessment. FAHR-Face, an #AI model, estimates biological age & mortality risk to help inform more personalized treatment decisions. ▪️Raymond Mak, MD & Hugo Aerts, PhD | @LancetDigitalH 🔗 ascopost.com/news/october-20…

🚺 Investigational B7-H4–targeted ADC mocertatug rezetecan (Mo-Rez) demonstrated early activity in phase I BEHOLD-1, with response rates of 62% in platinum-resistant #OvarianCancer, 67% in advanced #EndometrialCancer at higher doses. ▪️Ana Oaknin, MD 🔗 ascopost.com/news/october-20…

🧬A study of more than 240,000 patients across 200+ #communityoncology practices found substantial growth in advanced biomarker testing and novel therapy use for metastatic #BreastCancer and #LungCancer. 🔹 Stephen “Fred” Divers, MD | #ASCOQLTY26 🔗 ascopost.com/news/october-20…

💻 #ASCOAI: A new @FDA-cleared #AI tool could help refine preoperative treatment planning for HR-positive, HER2-negative #BreastCancer. TumorSight Risk combines MRI, pathology, and clinical data to generate a personalized recurrence risk score. 🔗 ascoai.org/articles/2026/10/…

🫁 Which #LungCancer studies from #ASCO26 could influence clinical practice? Apar Kishor Ganti, MD, MS, FASCO (@AparGanti) highlights key findings in targeted therapies, immunotherapy, and emerging treatment strategies for #NSCLC and #SCLC. Learn more ➡️ ascopost.com/news/october-20…

🏡Improved survival in #PediatricLeukemia does not eliminate the burden on families. A new study underscores the need for early, ongoing caregiver support, routine screening for financial toxicity and household disruptions. ▪️Dr. Rozalyn Rodwin | @JNCCN ascopost.com/news/october-20…

📊Two @AmericanCancer studies presented at #ASCOQLTY26 found widening #BreastCancer survival and mortality disparities over time between rural and urban communities, highlighting persistent gaps in access to cancer care. Explore the findings ➡️ ascopost.com/news/october-20…

🩻 #ASCOAI: Could #AI help improve radiation oncology training? A randomized phase II trial found that AI auto-segmentation improved contour quality and efficiency among novice practitioners performing #ProstateCancer brachytherapy. Learn more 👉 ascoai.org/articles/2026/10/…

2️⃣ studies highlight emerging therapies for AL #Amyloidosis. Anselamimab showed a survival signal in prespecified subgroup, while linvoseltamab demonstrated deep hematologic and organ responses in early-phase research. 🔹Drs. Wechalekar & Lee | #ASCO26 ascopost.com/news/october-20…

🚨 #FDAApproval: The @FDA has granted accelerated approval to dostarlimab (Jemperli) for adults with stage II/III MSI-H/dMMR locally advanced #RectalCancer. In AZUR-1, the ORR was 79%, with a 47% sustained clinical CR rate at 12 months. 🔗 ascopost.com/news/october-20…

🩸In the phase III EXCALIBER-RRMM trial, iberdomide + daratumumab + dexamethasone improvedMRD-negative CR rates vs the bortezomib-based regimen (41% vs 21%) in patients with relapsed/refractory #MultipleMyeloma. 🔸@SagarLonialMD | @TheLancetOncol 🔗 ascopost.com/news/october-20…

🔍 Nearly half (48%) of patients with high-risk #Melanoma developed chronic immune-related adverse events after adjuvant anti–PD-1 therapy. ➡️ At a median follow-up of 67 months, 34% had ongoing toxicity ▪️Douglas B. Johnson, MD | @JAMANetworkOpen ascopost.com/news/october-20…

🤝@ASCO and @WHO have signed a collaboration agreement that is focused on: 1⃣ building professional competencies in #CancerCare 2⃣ improving access to #clinicaltrials 3⃣ strengthening quality, accessibility & accountability in #cancer care Learn more ➡️ ascopost.com/news/october-20…